Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Adrenocortical Carcinoma 2

Interventions

Mitotane 2pembrolizumab 1milademetan 1cixutumumab 1antineoplaston AS 2-1 1antineoplaston A10 1Suramin 1Nivolumab 1Hydrocortisone 1Dichlorodiphenyldichloroethane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Adrenocortical Carcinoma × Mitotane × Clear all
NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT00778817 2014-04-29

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
20 enrolled 17 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡